Disposals of Own Shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:


Date of transaction


LTI Plan

Number of disposed



UCB shares







21 January 2022


Stock Option Plan 2012


€ 32,36


25 January 2022


Stock Option Plan 2012


€ 32,36

This press release is available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T 32.2.559.94.14 [email protected]

Corporate Communications
Laurent Schots 
Media Relations, UCB  
T 32.2.559.92.64  [email protected] 

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news